Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report released on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of NASDAQ CARA opened at $5.36 on Tuesday. The business has a 50-day moving average of $3.91 and a two-hundred day moving average of $3.78. The company has a market capitalization of $294.03 million, a price-to-earnings ratio of -3.06 and a beta of 0.64. Cara Therapeutics has a 1 year low of $2.71 and a 1 year high of $13.80.

Institutional Trading of Cara Therapeutics

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Cara Therapeutics in the third quarter valued at approximately $29,000. FMR LLC raised its holdings in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 32,789 shares during the last quarter. Finally, Disciplined Growth Investors Inc. MN boosted its stake in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 120,660 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.